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Edited by Barry HalliwellAbstract The present one-drug-one-target paradigm in drug
discovery has been considered partially responsible for the
more-funding-less-drug predicament in modern pharmaceutical
industry. To hit the multiple targets implicated in complex dis-
eases, two strategies, based on multicomponent or single-ingredi-
ent, are conceivable. Although the latter is more diﬃcult to be
fulﬁlled than the former, the recent progress made in the ﬁght
against Alzheimers disease (AD) has brought us the ﬁrst light
of success of the latter strategy. In this review, both synthetic
and natural multipotent agents are described, which hit two or
more targets implicated in AD, e.g., acetylcholinesterase, mono-
amine oxidase, amyloid-b, s protein, metal ions and reactive oxy-
gen species. Nevertheless, due to the potential risks in safety,
absorbability and pharmacokinetics of synthetic multipotent
agents, natural counterparts seem more promising in the future
development.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Modern pharmaceutical industry is facing unprecedented
challenges in drug development. The global research funding
has doubled since 1991, but the approved new drugs have fall-
en by 50% [1]. Considering the fact that most human diseases,
such as cancer, diabetes, heart disease, arthritis and neurode-
generative diseases, involve multiple pathogenetic factors, the
more-funding-less-drug predicament is attributed in part to
the limitations of the present one-drug-one-target paradigm
in drug discovery [1,2]. Therefore, more and more eﬀort is de-
voted to ﬁnding new therapeutics aiming at multiple targets
[2], which is becoming a new paradigm in drug discovery.
To hit the multiple targets implicated in the complex dis-
eases, two strategies are conceivable. One is called multicom-
ponent therapeutic strategy, which incorporates two or more
active ingredients in one drug [2]. In fact, this strategy has been
successfully used in traditional medicine (in China and many
other countries) for thousands of years and in current drug*Fax: +0086 533 2780271.
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attempts to employ one compound to hit the multiple targets,
which can be termed as one-compound-multiple-targets strat-
egy. Although the latter strategy seems more convenient than
the former, it is more diﬃcult to be fulﬁlled. Nevertheless,
the accumulating experience gained in the battle against
Alzheimers disease (AD) displays the feasibility of the latter
strategy.
AD, characterized by progressive memory loss, decline in
language skills and other cognitive impairments, has been a
major threat to ageing population [3,4]. Although the etiology
of AD is not very clear, multiple factors, such as amyloid-b
(Ab) and s protein aggregation, excessive metal ions (e.g.,
Cu2+, Zn2+, Fe3+), oxidative stress and reduced acetylcholine
(ACh) level, have been considered to play important roles in
the pathogenesis of AD [3–6]. This provides diverse targets
for screening AD-modifying drugs. Indeed, numerous syn-
thetic or natural molecules have been screened to decrease
Ab production (e.g., b-secretase inhibitor), to prevent Ab or
s aggregation, to chelate transition metals, to scavenge reactive
oxygen species (ROS) or to inhibit acetylcholinesterase
(AChE) or monoamine oxidase (MAO) [3–7]. However, the
success of the one-drug-one-target strategy is limited, which
has stimulated the search for more eﬃcient combined weapons
to combat AD.2. Synthetic compounds as multipotent agents
Some pioneers resorted to incorporating two or more phar-
macophores in one molecule to design multipotent agents to
hit more than one target in AD. Several pioneering studies at-
tempted to combine AChE and MAO inhibiting activity. Fink
et al. [8] showed that hybrid of an AChE inhibitor (i.e., physo-
stigmine) and an irreversible MAO inhibitor, such as L-depre-
nyl, resulted in dual AChE and MAO inhibitors. Furthermore,
they found that a series of imino 1,2,3,4-tetrahydrocyclo-
pent[b]indole carbamates (Fig. 1) are eﬃcient dual AChE
and irreversible MAO inhibitors too [8]. Bru¨hlmann et al. [9]
discovered that some coumarin and chromone derivatives
(Fig. 1) can behave as inhibitors of both MAO (mainly
MAO-B) and AChE. By incorporating two pharmacophores
in inhibiting AChE and MAO-B, i.e., carbamate and propar-
gyl group, into a single molecule scaﬀold, Sterling et al. [10]
also gained novel dual inhibitors of AChE and MAO.
Besides hydrolyzing ACh, AChE also functions as a
promoter of Ab ﬁbril formation, which is independent of itsblished by Elsevier B.V. All rights reserved.
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Fig. 1. Synthetic multipotent compounds to combat Alzheimers disease. The targets for each molecule are indicated in the parentheses. A basic
principle to design multipotent compounds is incorporating two or more pharmacophores in one molecule. Despite the in vitro success of these
synthetic agents, the potential risks in safety, absorbability and pharmacokinetics is a big hurdle in their further development.
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eral binding site of AChE [11]. This stimulated the interest to
design hybrid molecules to inhibit AChE and AChE-induced
Ab aggregation simultaneously. Piazzi et al. [12] achieved this
goal by linking a benzylamino group and a coumarin heterocy-
cle through a phenyl ring. The combined molecule (AP2238)
(Fig. 1) is able to contact both the catalytic and the peripheral
binding sites of AChE at the same time. Moreover, Rosini
et al. [13] rationally designed a novel compound (lipocrine)
(Fig. 1) by linking tacrine, a AChE inhibitor, and lipoic acid,
a universal antioxidant, and endowed the hybrid molecule with
three functions, i.e., inhibiting the catalytic activity of AChE
and AChE-induced Ab aggregation and protecting against
ROS. Melchiorre et al. [14] showed that a polyamine, caproc-
tamine (Fig. 1), is well balanced between an AChE inhibitor
and a competitive muscarinic M2 receptor antagonist, which
means that caproctamine will stimulate cholinergic activity in
the brain by decreasing ACh hydrolysis rates and by enhancing
ACh release in the synapse at the same time. More interest-
ingly, caproctamine also has potential to prevent AChE-
induced Ab aggregation by interacting with the peripheral
binding sites of AChE [14].
Considering the preliminary success of metal chelators (e.g.,
clioquinol) in treating AD [5,15] and the fact that some super-
oxide dismutase (SOD) mimetics are metal chelates, Ji et al.
[16] proposed that better clinical eﬀects than clioquinol canbe expected for a SOD-mimetic ligand with metal-binding abil-
ity comparable with clioquinol, because the ligand bears me-
tal–protein-attenuating ability and radical-scavenging
potential in one structure. By means of quantum chemical cal-
culation, two metal chelators, 1-BYT and 1,4-BYT (Fig. 1)
were revealed to be qualiﬁed candidates to fulﬁll this strategy
[16].3. Natural products as multipotent agents
Despite the in vitro success of synthetic multifunctional
agents, the potential risks in safety, absorbability and pharma-
cokinetics is a big hurdle in their further development [8].
Hence, it is exciting to note that some natural products also
hold multiple functions, among which, curcumin (Fig. 2) is gi-
ven the most attention. The beneﬁcial eﬀect of curcumin to
prevent AD has been shown by transgenic mouse experiment
[17] and epidemiologic investigation that AD prevalence is
only 1% in people over age 65 of rural India, where turmeric
is commonly used in food [18]. The AD-preventing mechanism
of curcumin was naturally related to its well known antioxi-
dant and anti-inﬂammatory activities [19,20]. However, recent
in vitro and in vivo experiments revealed that curcumin can
block Ab aggregation with high eﬃciency (IC50 < 1 lM)
[21,22]. In addition, curcumin is also a good metal chelator
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Fig. 2. Natural multipotent compounds to combat Alzheimers disease (AD). The targets for each molecule are indicated in the parentheses. As
catechol group serves as a metal ligand and a radical scavenger and is required in retarding Ab aggregation, it is likely a multifunctional
pharmacophore. Thus, catechol provides a good starting point for screening and designing AD-modifying drugs. To reduce the prooxidant danger of
catechol, catechol-containing xanthones are recommended, because the perfect conjugation of rings A, B and electron-withdrawing ring C (1,4-
pyrone) attenuates their electron-donating ability. More interestingly, some xanthones have been revealed as eﬃcient AChE and MAO inhibitors.
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tion indicated that curcumin can eﬃciently sequester Cu2+ and
the Cu2+-curcumin complex gets more active than the parent
curcumin in scavenging ROS by catalyzing the dismutation
of superoxide anion radical [24] or by donating a proton or
an electron [25]. Therefore, all of the evidence implies that cur-
cumin is a very promising multipotent compound to treat AD.
Besides curcumin, ﬂavonoids, such as gossypetin, ()-epicat-
echin-3-gallate and myricetin (Fig. 2), are pleiotropic natural
products too. They have long been known as excellent ROS
scavengers endowed with high metal-chelating ability [26].
Moreover, Taniguchi et al. [27] revealed that these ﬂavonoids
hold Ab- or s-aggregation-inhibiting capability with IC50
lower than 5 lM. The diﬀerent structures of curcumin and
ﬂavonoids suggest that the structural requirements to fulﬁll
the multifunction are diverse and thus, it can be expected
to ﬁnd more candidates from natural product libraries.
Considering the wide enzyme-inhibiting spectra of curcumin
and ﬂavonoids, it is challenging to investigate their eﬀects on
other AD-related proteins. Maybe, more AD-attenuating
mechanisms can be revealed for both kinds of natural products.
As revealed by the structure–activity relationship study on
ﬂavonoids [26,28], catechol moiety is an active center to scav-
enge ROS or bind metal ions. On the other hand, catechol is
also required, e.g., in apomorphine, to prevent Ab aggregation
[29]. Therefore, catechol likely plays a key role in exerting the
multifunction of ﬂavonoids and can be regarded as a multi-
functional pharmacophore, which means that the multiple tar-
gets in AD can be hit not only by one compound but also by
one pharmacophore. The feasibility of this new concept is fur-
ther supported by an intriguing ﬁnding that there exist com-
mon peptide motifs in AD-related proteins. By bioinformatic
analyses on 43 proteins implicated in AD, Stephenson et al.
[30] identiﬁed BBXB and AXBBXB (where B is a basic residue,
X represents any other amino acids and A refers to an acidic
residue) as two common receptor motifs. BBXB motif occursin 27 proteins, while AXBBXB motif is shared by 8 proteins
and holds higher speciﬁcity. The common motifs will serve
as the targets of multifunctional pharmacophores, which in-
deed boosts up the practicability of the one-compound- multi-
ple-targets strategy in combating AD.
Although catechol is of great interest in AD-attenuating
drug discovery, there is concern about its potential toxicity
[31]. The toxicity of catechols may arise from its strong elec-
tron-donating ability, which will change the antioxidant to a
prooxidant. In addition, the toxicity of catechols is likely asso-
ciated with their quinone formation potential. It was revealed
that the less quinone is formed, the safer the catechols [31].
These ﬁndings oﬀer important clues to screening or designing
catechol-based multipotent agents. For instance, catechol-con-
taining xanthones (Fig. 2) may have more potential than ﬂavo-
noids to act as pleiotropic agents to combat AD, because the
perfect conjugation of rings A, B and electron-withdrawing
ring C (1,4-pyrone) attenuates their electron-donating ability
[32]. More interestingly, xanthones have really been revealed
as eﬃcient AChE and MAO inhibitors [33,34].4. Conclusion
Drug discovery paradigm is shifting from one-drug–one-tar-
get strategy to one-drug-multiple-targets strategy. The diverse
targets can be hit not only by multiple components but also by
one compound or even by a single pharmacophore. Thanks to
the advancement in high throughput drug screening and com-
puter-aided drug design, there is less and less technical hurdle
in ﬁnding more multipotent agents to fulﬁll the new strategy.
Especially, the recent progress made in ﬁghting against AD
has brought us the ﬁrst light of success of the new concept,
which also has important implications for treating other neu-
rodegenerative diseases [35], because similar multiple pathoge-
netic factors, such as protein aggregation, excessive ROS and
H.-Y. Zhang / FEBS Letters 579 (2005) 5260–5264 5263metals, are involved [5,6] and diﬀerent types of soluble amyloid
oligomers bear a common structure [36].
Note. Following the acceptance of the review, two interest-
ing papers appeared [37,38], in which Youdim and coworkers
reported that some designed iron chelators hold MAO-AB
inhibitory activity and antioxidant eﬀect, thus can serve as
multipotent agents to combat AD and Parkinsons disease.
In addition, from the references of both papers, I found a pio-
neering review on multifunctional drugs to treat neurodegener-
ative disorders [39], which is very helpful to the researchers in
this area.Acknowledgements: This work was supported by the National Basic
Research Program of China (2003CB114400) and the National Natu-
ral Science Foundation of China (30100035).References
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